FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Commission granted a marketing authorisation valid throughout the EU for Effentora on 4 April 2008.
Estonian: Euroopa Komisjon andis Effentora müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 4. Aprillil 2008.
English: A risk management plan has been developed to ensure that Effentora is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Effentora võimalikult ohutu kasutamine.
English: The full EPAR for Effentora can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Effentora kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Alternatively, the tablets can be placed under the tongue.
Estonian: Tabletid võib asetada ka keele alla.
English: Patients should be closely monitored for these side effects.
Estonian: Patsiente tuleb nende kõrvalnähtude suhtes hoolikalt jälgida.
English: What measures are being taken to ensure the safe and effective use of Effentora?
Estonian: Mis meetmed võetakse, et tagada Effentora ohutu ja efektiivne kasutamine?
English: This medicine can only be obtained by ‘special' prescription.
Estonian: Seda ravimit saab üksnes eriretsepti alusel.
English: Because fentanyl has been in use for many years, the company presented data from the scientific literature, as well as from studies that it had carried out.
Estonian: Et fentanüüli on kasutatud palju aastaid, esitas ettevõte teaduskirjandusest ja samuti ettevõtte tehtud uuringutest pärit andmed.
English: The tablets usually dissolve in 14 to 25 minutes, releasing the active substance, which is absorbed directly into the bloodstream.
Estonian: Tabletid lahustuvad tavaliselt 14-25 minutiga, vabastades toimeaine, mis imendub otse vereringesse.
English: After 30 minutes, any pieces of tablet remaining can be swallowed with a glass of water.
Estonian: 30 minuti pärast võib järelejäänud tabletitükid klaasi veega neelata.
English: The tablets should not be broken or crushed, and they should not be sucked, chewed or swallowed whole.
Estonian: Tablette ei tohi murda ega purustada, samuti imeda, närida ega tervelt neelata.
English: They should only have the necessary strengths of Effentora tablets available at any one time, to prevent confusion and possible overdose.
Estonian: Neil tohivad olla korraga ainult vajaliku tugevusega Effentora tabletid, et vältida segiajamist ja võimalikku üleannustamist.
English: The most common side effects with Effentora (that may affect more than 1 patient in 10) are dizziness, headache, nausea (feeling sick), vomiting, and reactions at the site of application including bleeding, pain, ulcers, irritation, unusual sensations, numbness, redness, swelling and spots.
Estonian: Effentora kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peapööritus, peavalu, iiveldus, oksendamine ja manustamiskoha reaktsioonid, sealhulgas verejooks, valu, haavandid, ärritus, vääraistingud, tuimus, punetus, turse ja laigud.
English: The most serious of these are respiratory depression (inhibition of breathing), circulatory depression (slow heartbeat), hypotension (low blood pressure) and shock (a steep fall in blood pressure).
Estonian: Neist kõige raskekujulisemad on respiratoorne depressioon (hingamispeetus), vereringe depressioon (südametegevuse aeglustumine), hüpotensioon (madal vererõhk) ja šokk (vererõhu järsk langus).
English: This is a summary of the European public assessment report (EPAR) for Effentora.
Estonian: See on ravimi Effentora Euroopa avaliku hindamisaruande kokkuvõte.
English: The company that makes Effentora will also provide educational materials in each European Union (EU) Member State to make sure that patients and doctors are aware of how the medicine should be used safely, the risks of accidental exposure to fentanyl and how to dispose of Effentora.
Estonian: Effentora tootja koostab ka õppematerjalid igas Euroopa Liidu liikmesriigis, et tagada patsientidele ja arstidele teave ravimi ohutu kasutamise, fentanüüliga juhusliku kokkupuute riskide ja Effentora kõrvaldamise kohta.
English: The CHMP decided that Effentora's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Effentora kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The ability of Effentora to treat breakthrough pain was tested in two main studies involving a total of 150 adults with cancer who were being treated with opioids.
Estonian: Effentora valuvaigistavat mõju läbimurdevalu ravis uuriti kahes põhiuuringus, milles osales kokku 150 täiskasvanud vähipatsienti, keda raviti opioididega.
English: Patients should not eat or drink anything while the tablet is in the mouth.
Estonian: Patsient ei tohi tableti suus hoidmise ajal mitte midagi süüa ega juua.
English: Effentora can also cause the side effects typically seen with other opioids, but these tend to decrease or stop with continued use.
Estonian: Effentora võib tekitada ka teiste opioidide tüüpilisi kõrvalnähte, kuid kasutamist jätkates need enamasti vähenevad või kaovad.
English: Effentora fentanyl
Estonian: Effentora fentanüül
English: In both studies, each patient was treated during 10 separate episodes of breakthrough pain: in seven of these episodes, each patient received Effentora, and in the other three episodes, each patient received placebo (a dummy tablet).
Estonian: Mõlemas uuringus raviti igal patsiendil 10 eraldi läbimurdevalu episoodi: neist 7 episoodi korral manustati igale patsiendile Effentorat ja ülejäänud 3 episoodi korral manustati igale patsiendile platseebot (näiv ravim).
English: The main measure of effectiveness was the change in pain intensity over the first 30 or 60 minutes after taking the tablet.
Estonian: Efektiivsuse põhinäitaja oli esimese 30 või 60 minuti jooksul pärast tableti manustamist toimunud muutus valu tugevuses.
English: There must be a gap of at least four hours between treating each episode of pain.
Estonian: Valuepisoodide ravimise vahele peab jätma vähemalt neli tundi.
English: Doses of Effentora above 800 micrograms have not been tested.
Estonian: Effentora annuseid üle 800 µg ei ole kontrollitud.
English: Other information about Effentora
Estonian: Muu teave Effentora kohta
English: It must not be used to treat short-term pain other than breakthrough pain.
Estonian: Ravimit ei tohi kasutada muu lühiajalise valu kui läbimurdevalu raviks.
English: For more information about treatment with Effentora, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Effentoraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Once the appropriate dose for the patient has been found, the patient should take this dose as a single tablet.
Estonian: Kui patsiendile sobiv annus on kindlaks määratud, võtab patsient selle annuse ühe tabletina.
English: Effentora must not be used in patients who are not already taking opioids to maintain pain control, who have severe respiratory depression, or who have severe obstructive lung conditions (diseases that severely impede breathing).
Estonian: Effentorat ei tohi kasutada patsiendid, kes veel ei kasuta taustavalu leevendamiseks opioide või kellel on raske hingamispuudulikkus või raske obstruktiivne kopsuhaigus (haigused, mis raskelt takistavad hingamist).
English: When a patient starts to take Effentora, the doctor will need to work out the appropriate individual dose that will provide adequate pain relief for the patient with few side effects.
Estonian: Kui patsient alustab Effentora kasutamist, peab arst leidma talle individuaalselt sobiva annuse, mis leevendab piisavalt patsiendi valu ega tekita palju kõrvalnähte.
English: Effentora is a medicine that contains the active substance fentanyl.
Estonian: Effentora on ravim, mis sisaldab toimeainena fentanüüli.
English: This means that because the medicine can be misused or cause addiction, it is used under stricter conditions than normal.
Estonian: See tähendab, et seda ravimit kasutatakse rangemates tingimustes kui tavalisi ravimeid, sest ravim võib põhjustada kuritarvitamist või narkomaaniat.
English: Effentora was more effective than placebo in reducing pain in both studies.
Estonian: Effentora oli mõlemas uuringus valu leevendamisel efektiivsem kui platseebo.
English: If this dose stops controlling the pain well enough, the doctor will need to work out a new individual dose.
Estonian: Kui nimetatud annus ei leevenda enam valu piisavalt, määrab arst uue individuaalse annuse.
English: Effentora is used to treat ‘breakthrough' pain in adults with cancer who are already using opioids (a group of painkillers that includes morphine and fentanyl) to control long-term cancer pain.
Estonian: Effentorat kasutatakse läbimurdevalu raviks täiskasvanud vähipatsientidel, kes juba kasutavad pikaajalise vähivalu vaigistamiseks opioide (valuvaigistite rühm, kuhu kuuluvad morfiin ja fentanüül).
English: In the second study, pain intensity had fallen by 9.7 points at 60 minutes after Effentora and by 4.9 points after placebo.
Estonian: Teises uuringus vähenes patsientidel valu tugevus 60 minuti jooksul pärast Effentora manustamist 9,7 punkti võrra ja pärast platseebo manustamist 4,9 punkti võrra.
English: Breakthrough pain is when a patient experiences additional, sudden pain in spite of ongoing treatment with painkillers.
Estonian: Läbimurdevalu on äkiline täiendav valuaisting, mis tekib vaatamata senisele valuvaigistitega ravile.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Effentora, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Effentora omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Effentora.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What is Effentora?
Estonian: Mis on Effentora?
English: Why has Effentora been approved?
Estonian: Miks Effentora heaks kiideti?
English: Effentora is taken at the start of a breakthrough pain episode.
Estonian: Effentorat manustatakse läbimurdevalu episoodi tekkimisel.
English: The patient should be monitored carefully while the dose is increased.
Estonian: Annuse suurendamise ajal tuleb patsienti hoolikalt jälgida.
English: For the full list of all side effects reported with Effentora, see the package leaflet.
Estonian: Effentora kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In the first study, pain intensity had fallen by an average of 3.2 points at 30 minutes after the patients took Effentora and by 2.0 points after they took placebo.
Estonian: Esimeses uuringus vähenes patsientidel valu tugevus 30 minuti jooksul pärast Effentora manustamist keskmiselt 3,2 punkti võrra ja pärast platseebo manustamist 2,0 punkti võrra.
English: The active substance in Effentora, fentanyl, is an opioid.
Estonian: Effentora toimeaine fentanüül on opioid.
English: Patients should not possess or use any other medicines containing fentanyl for the treatment of breakthrough cancer pain at the same time as using Effentora.
Estonian: Patsiendid ei tohi vähist tingitud läbimurdevalu leevendamiseks omada ega kasutada samaaegselt Effentoraga muid fentanüüli sisaldavaid ravimeid.
English: In Effentora, it is given as a buccal tablet, so that the fentanyl is absorbed through the lining of the mouth.
Estonian: Effentora sisaldab fentanüüli suus lahustuva tableti kujul, millest fentanüül imendub suu limaskesta kaudu.
English: What is the risk associated with Effentora?
Estonian: Mis riskid Effentoraga kaasnevad?
English: The tablets should be removed from the packaging immediately before being placed between the gum and the cheek.
Estonian: Tablett tuleb võtta pakendist ja asetada kohe seejärel igeme ja põse vahele.
English: Once in the bloodstream, fentanyl acts on receptors in the brain and spinal cord to prevent pain
Estonian: Vereringes olev fentanüül mõjub pea- ja seljaaju retseptoritele, vaigistades valu.
English: It is available as ‘buccal tablets' (tablets that dissolve in the mouth).
Estonian: Seda turustatakse suus lahustuvate tablettidena.
English: What benefit has Effentora shown during the studies?
Estonian: Milles seisneb uuringute põhjal Effentora kasulikkus?
English: See the package leaflet for further information.
Estonian: Lisateave on pakendi infolehel.
English: How does Effentora work?
Estonian: Kuidas Effentora toimib?
English: What is Effentora used for?
Estonian: Milleks Effentorat kasutatakse?
English: How has Effentora been studied?
Estonian: Kuidas Effentorat uuriti?
English: Treatment with Effentora should be started by and remain under the guidance of a doctor who has experience in the management of opioid treatment in cancer patients.
Estonian: Ravi Effentoraga tohib alustada üksnes vähipatsientide opioidravis kogenud arst ning ravi peab toimuma tema järelevalve all.
English: How is Effentora used?
Estonian: Kuidas Effentorat kasutatakse?
English: EU/1/15/995/001 DUTREBIS 150 mg / 300 mg Film-coated tablet
Estonian: EU/1/15/995/001 DUTREBIS
English: Oral use bottle (HDPE)
Estonian: Suukaudne pudel (HDPE)
English: Pharmaceutical form Route of administration Immediate Packaging
Estonian: Sisepakendi iseloomustus
English: ATC Code: R01AD05
Estonian: ATC-kood: R01AD05
English: They should be treated additionally if needed.
Estonian: Neid tuleb vajadusel ravida täiendavalt.
English: The CHMP agrees with the responses.
Estonian: Inimravimite komitee nõustus vastustega.
English: The desired clinical effect appears within about 1-2 weeks.
Estonian: Soovitud kliiniline toime ilmneb ligikaudu 1-2 nädalaga.
English: White homogeneous suspension
Estonian: Valge homogeenne suspensioon
English: The patient should be informed that the full effect is not achieved until after a few days of treatment.
Estonian: Patsienti tuleb teavitada, et ravi täielik mõju saavutatakse alles mõnepäevase ravi järel.
English: OTHER SPECIAL WARNING(S), IF NECESSARY Shake the bottle
Estonian: TEISED ERIHOIATUSED (VAJADUSEL) Loksutage pudelit
English: You must use this medicine regularly or it will not work properly.
Estonian: Ravimit peab kasutama regulaarselt, sest muidu ei toimi see õigesti.
English: GROUNDS FOR POSITIVE OPINION
Estonian: POSITIIVSE OTSUSE ALUSED
English: Remove the protective cap.
Estonian: Eemaldage kaitsekork.
English: You are unlikely to experience any medical problems.
Estonian: Tõenäoliselt ei teki teil terviseprobleeme.
English: 6.5 Nature and contents of container Not all pack sizes may be marketed.
Estonian: 6.5 Pakendi iseloomustus ja sisu Kõik pakendi suurused ei pruugi olla müügil.
English: Veluwezoom 22 1327 AH Almere Netherlands
Estonian: Veluwezoom 22 1327 AH Almere Holland
English: Adults, adolescents and children from 6 years of age:
Estonian: Täiskasvanud, noorukid ja üle 6-aastased lapsed
English: After first opening: 3 months
Estonian: Pärast avamist: 3 kuud.
English: Undesirable effects frequencies were defined as follows:
Estonian: Kõrvaltoimete sagedused on määratuletud järgnevalt:
English: Shake the bottle (figure 1).
Estonian: Loksutage pudelit (joonis 1).
English: Protein binding is 85-90%.
Estonian: Plasmavalkudele seonduvus 85-90%.
English: The impact of the differences of the two preparations is unknown.
Estonian: Kahe ravimi erinevuse mõju ei ole teada.
English: C.F. Tietgens Boulevard 40 DK-5220 Odense SØ Danmark
Estonian: C.F. Tietgens Boulevard 40 DK-5220 Odense SØ Taani
English: Discard the opened bottle with any remaining solution after 3 months.
Estonian: Visake avatud pudel koos sellesse jäänud lahusega ära 3 kuu möödudes.
English: Be sure to tell your doctor immediately if you are pregnant, think you may be pregnant, or if you are planning to become pregnant.
Estonian: Teavitage oma arsti kohe, kui olete rase, kahtlustate endal rasedust või plaanite rasestuda.
English: Animal studies have shown reproductive toxicity (see section 5.3).
Estonian: Loomkatsetes on ilmnenud kahjulik toime reproduktiivsusele (vt 5.3).
English: Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines without a prescription.
Estonian: Palun informeerige oma arsti või apteekrit kui te kasutate või olete hiljuti kasutanud mingeid muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimeid.
English: You can either use this medicine:
Estonian: Te võite kasutada seda ravimit kas:
English: Hold the bottle as shown in figure 2.
Estonian: Hoidke pudelit nagu joonisel 2 näidatud.
English: The dosage should be determined individually.
Estonian: Annus tuleb valida individuaalselt.
English: To support the application, the Applicant submitted one clinical study in adults.
Estonian: Taotluse toetuseks esitas taotleja ühe täiskasvanutel tehtud kliinilise uuringu.
English: Clinically, the most important outcome measure of human growth is the final height in relation to the expected final height.
Estonian: Kliiniliselt kõige olulisem inimese kasvamistulemuse näitaja on lõpp-pikkus võrreldes eeldatava lõpp-pikkusega.
English: It should be sprayed into your nostrils as described below.
Estonian: Seda pihustatakse ninasõõrmetesse, nagu järgnevalt kirjeldatud.
English: ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S) OF THE MEDICINAL PRODUCT(S), ROUTE(S) OF ADMINISTRATION, APPLICANT(S) IN THE MEMBER STATES
Estonian: LISA I RAVIMI(TE) NIMETUSTE, RAVIMVORMI(DE), TUGEVUS(T)E, MANUSTAMISVIISI(DE), TAOTLEJA(TE) LOETELU LIIKMESRIIKIDES
English: Budesonide is eliminated through metabolism, mainly by the enzyme CYP3A4.
Estonian: Budesoniid elimineeritakse metaboolsel teel, peamiselt ensüümi CYP3A4.vahendusel.
English: The volume of distribution of budesonide is approximately 3 L/kg.
Estonian: Budesoniidi jaotusruumala on ligikaudu 3 l/kg.
English: Rare: osteoporosis (with longterm treatment)
Estonian: Harv: osteoporoos (pikaajalise ravi korral)
English: • if you have had an operation on your nose or any other injury to your nose that has not yet fully recovered
Estonian: • kui teil on olnud ninaoperatsioon või muu ninavigastus, mis ei ole veel täielikult paranenud;
English: Children should be treated under guidance of an adult.
Estonian: Laste ravi peab toimuma täiskasvanu järelevalve all.
English: However, disagreement between the member states involved in the procedure regarding the inclusion of children and adolescents remained, and the procedure was referred to the CHMP.
Estonian: Menetluse käigus selgunud liikmesriikidevahelised erimeelsused laste ja noorukite lisamise kohta jäid siiski püsima ning menetlemine suunati inimravimite komiteesse.
English: The Applicant stated that growth is divided into 3 distinct age-related phases and that conclusions from studies in one age group cannot be generalised to other age groups.
Estonian: Taotleja märkis, et kasv on jagatud kolmeks kindlaks vanusega seotud faasiks ja ühes vanuserühmas tehtud uuringute tulemusi ei saa üldistada teistele vanuserühmadele.
English: • if you have been taking this medicine continuously for a long time, your doctor will want to examine the inside of your nose at least every six months
Estonian: • kui olete seda ravimit kasutanud pidevalt pikema aja vältel, kontrollib arst teie nina vähemalt iga kuue kuu järel;
English: Corticosteroids are a group of medicines which help fight inflammation.
Estonian: Kortikosteroidid kuuluvad ravimite rühma, mis aitavad võidelda põletike vastu.
English: In continuous long-term treatment, the nasal mucosa should be inspected regularly e.g. every 6 months.
Estonian: Pideva pikaajalise ravi ajal tuleb ninalimaskesta regulaarselt kontrollida (nt iga 6 kuu järel).
English: • if you are a child and are taking high doses of this medicine for a long time, your doctor will check your height regularly
Estonian: • kui olete laps ja saate seda ravimit suurtes annustes ning pikaajaliselt, peab arst regulaarselt kontrollima teie pikkust;
English: Ascorbic acid E 300
Estonian: Askorbiinhape E 300
English: The main metabolites 6-beta-hydroxybudesonide and 16-alpha-hydroxyprednisolon are almost ineffective.
Estonian: Peamised metaboliidid 6-beeta-hüdroksübudesoniid ja 16-alfa-hüdroksüprednisoloon on praktiliselt toimeta.
English: Budesonide Sandoz has no influence on the ability to drive or use machines.
Estonian: Budesonid Sandoz ei oma toimet autojuhtimise ja masinate käsitsemise võimele.
English: Budesonide Sandoz and the originator product have the same pharmaceutical form, contain the same amount of active substance and have identical delivery devices.
Estonian: Budesonide Sandoz ja originaalravim on sama ravimivormiga, sisaldavad sama koguse toimeainet ja neil on identsed manustamisseadmed.
English: Special care is needed in patients with tuberculosis.
Estonian: Tuberkuloosiga patsiendid vajavad eriravi.
English: The metabolites are eliminated in the urine in unchanged or conjugated form.
Estonian: Metaboliidid väljutatakse uriiniga muutumatul kujul ja konjugaatidena.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Label
Estonian: MINIMAALSED NÕUDED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL Etikett
English: Like all medicines, Budesonide Nasal Spray can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka Budesonid ninasprei põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: For example, if you have hay fever, start using this medicine about 2 weeks before your hay fever symptoms usually begin to be a problem and stop using this medicine after the end of season of allergen exposure.
Estonian: Kui teil on näiteks heinapalavik, hakake seda ravimit kasutama ligikaudu 2 nädalat enne tavapärast heinapalaviku tekkeaega ning lõpetage ravimi kasutamine allergeeniga kokkupuute perioodi lõppedes.
English: Gently blow your nose to clean the nostrils, if necessary.
Estonian: Vajadusel nuusake nina puhtaks.
English: Spray once (or more if your doctor has told you to).
Estonian: Pihustage ravimit ühe korra (või rohkem, kui arst on teid nii juhendanud).
English: Do not stop treatment even if you feel better unless told to by your doctor.
Estonian: Ärge lõpetage ravi ka siis, kui tunnete end paremini, va kui arst ei on teid eelnevalt nii juhendanud.
English: Important: Pump may need to be primed before use (see enclosed instructions) EXPIRY DATE
Estonian: Enne kasutamist võib pump vajada ettevalmistamist (vt kaasasolevaid juhiseid)
English: If you don't experience an immediate relief, you should continue using your medicine regularly as it may take a few days to start working.
Estonian: Kui haigusnähud ei leevendu kohe, jätkake regulaarset ravimi kasutamist, sest toime võib alata mõne päeva möödudes.
English: • The active substance(s) is (are)…
Estonian: • Toimeaine(d) on…
English: Insert the tip of the nozzle into your nostril as shown in figure 3 and spray once (or more if your doctor has told you to).
Estonian: Asetage otsik ninasõõrmesse, nagu näidatud joonisel 3, ning pihustage ravimit ühe korra (või rohkem, kui arst on teid nii juhendanud).
English: Maintenance dose It takes 7 to 14 days for this medicine to work.
Estonian: Säilitusannus See ravim hakkab mõjuma 7-14 päeva jooksul.
English: If this happens, first check if the nozzle is primed with medicine (see earlier).
Estonian: Kui nii peaks juhtuma, siis kontrollige esmalt, kas otsik on ravimiga täidetud (vt eespoolt).
English: Question 1c
Estonian: Küsimus 1c
English: Question 1a
Estonian: Küsimus 1a
English: Raiffeisenstraße 11 83607 Holzkirchen Germany
Estonian: Raiffeisenstraße 11 83607 Holzkirchen Saksamaa